Status:
COMPLETED
Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers
Lead Sponsor:
Haiquan Chen
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Immunotherapy effectiveness and optimal combination strategy in lung cancers with EGFR uncommon and 20ins mutations was unclear. Based on 627 lung adenocarcinoma patients harboring EGFR mutations and ...
Eligibility Criteria
Inclusion
- age≥18 years,
- advanced or recurrent LUAD confirmed by pathology,
- harboring EGFR mutations confirmed by super amplification refractory mutation system (super-ARMS) or next-generation sequencing (NGS),
- receiving anti-PD-(L)1 antibody therapy at least once,
- Radiologically evaluable according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
Exclusion
- \-
Key Trial Info
Start Date :
November 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 29 2023
Estimated Enrollment :
627 Patients enrolled
Trial Details
Trial ID
NCT06164574
Start Date
November 1 2022
End Date
November 29 2023
Last Update
December 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chaoqiang Deng
Shanghai, Please Select, China, 200032